摘要
目的研究原发性高血压(EH)患者血清中转化生长因子β1(TGF-β1)、B细胞淋巴瘤/白血病-2(Bcl-2)的浓度在依那普利和非洛地平治疗前后浓度的变化及临床意义。方法采用酶联免疫吸附法(ELISA)测定60例EH患者分别应用依那普利、非洛地平前后血清Bcl-2、TGF-β1浓度,并与30例健康人对照。结果与健康对照组相比,所有EH患者的TGF-β1、Bcl-2浓度均增高(P<0.01),应用降压药物依那普利及非洛地平治疗10d,两者降压作用相似,且均能使TGF-β1和Bcl-2浓度下降,但依那普利使这两种蛋白浓度改变更明显。结论Bcl-2、TGF-β1可能通过介导血管增生、重塑及部分通过凋亡参与原发性高血压发生、发展的病理过程,依那普利可能通过肾素-血管紧张素系统部分介导凋亡,减少TGF-β1、Bcl-2的合成。保持一定的细胞凋亡对维持血管正常结构和功能有重要意义。为进一步阐明高血压病发病机制及治疗提供理论论据。
Objective To observey the altered blood concentration of Bcl-2,TGF-β_1 and the clinical significance in patients with essential hypertension (EH) after yenazepril and felodipine administration. Methods Blood concentration of Bcl-2 and TGF-β_1 were measured in 60 patients with EH by ELISA before and after yenazepril and felodipine administration ,and were compared with 30 members of a healthy control group. Results Bcl-2 and TGF-β_1 concentration were higher in patients with hypertension than normotensive subject(P<0.01);Treatment of hypertensive patients with antihypertensive drugs caused a reduction in Bcl-2 and TGF-β_1 concentration ,which was more significant after administration of yenazepril than felodipine despite of the similar antihypertension effect.Conclusion Increased Bcl-2 and TGF-β_1 concentration in EH patients may contribute to the pathogesis of the disease through the vascular remodeling ,hypertrophy and partly apoptosis, yenazepril has greatly benefit in vascular architecture.
出处
《中国心血管杂志》
2005年第3期204-206,共3页
Chinese Journal of Cardiovascular Medicine